Global Life Science CDMO Market Growth (Status and Outlook) 2024-2030

Global Life Science CDMO Market Growth (Status and Outlook) 2024-2030

The global Life Science CDMO market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Life Science CDMO Industry Forecast” looks at past sales and reviews total world Life Science CDMO sales in 2023, providing a comprehensive analysis by region and market sector of projected Life Science CDMO sales for 2024 through 2030. With Life Science CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Life Science CDMO industry.

This Insight Report provides a comprehensive analysis of the global Life Science CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Life Science CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Life Science CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Life Science CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Life Science CDMO.

United States market for Life Science CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Life Science CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Life Science CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Life Science CDMO players cover Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics and Samsung Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Life Science CDMO market by product type, application, key players and key regions and countries.

Segmentation by type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others

Segmentation by application
Pharmaceutical
Clinical
Research

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences

Please note: The report will take approximately 2 business days to prepare and deliver.